Related Experiment Video

Updated: Apr 21, 2026

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.4K

Is testosterone deficiency a possible risk factor for priapism associated with sickle-cell disease?

Belinda F Morrison1, Uzoma A Anele, Marvin E Reid

  • 1Department of Surgery, University of the West Indies, Mona, Jamaica.

International Urology and Nephrology
|November 6, 2014
PubMed

Insights

Testosterone deficiency is common in men with sickle cell disease (SCD). This study found no direct link between testosterone deficiency and priapism in adult men with SCD.

Area of Science:

  • Andrology
  • Hematology
  • Endocrinology

Background:

  • Sickle cell disease (SCD) is a genetic blood disorder.
  • Priapism and testosterone deficiency are potential complications in men with SCD.

Purpose of the Study:

  • To investigate the association between testosterone deficiency and priapism in adult men diagnosed with sickle cell disease.

Main Methods:

  • A cross-sectional study involving 50 adult men with SCD (hemoglobin SS).
  • Collected blood samples for total and free testosterone, FSH, LH, prolactin, lipids, LDH, and hematological indices.
  • Utilized an interviewer-administered questionnaire to assess priapism history; defined testosterone deficiency as total testosterone <12 nmol/L.

Main Results:

  • Priapism occurred in 48% of patients, predominantly in those aged 18-25.
  • Testosterone deficiency was observed in 22% of patients, with 25% of those with priapism experiencing deficiency.
  • No significant difference in mean total testosterone, LH, or FSH levels was found between patients with and without a history of priapism.

Conclusions:

  • Testosterone deficiency is prevalent in men with SCD.
  • This study did not establish a direct association between testosterone deficiency and priapism in this cohort.
  • Further prospective research is required to clarify the relationship between priapism and testosterone deficiency in SCD patients.
Abstract

More Related Videos

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

1.3K
Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry08:23

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry

Published on: November 5, 2019

11.2K

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.2K
Spermatogenesis01:41

Spermatogenesis

Spermatogenesis is the process by which haploid sperm cells are produced in the male testes. It starts with stem cells located close to the outer rim of seminiferous tubules. These spermatogonial stem cells divide asymmetrically to give rise to additional stem cells (meaning that these structures “self-renew”), as well as sperm progenitors, called spermatocytes. Importantly, this method of asymmetric mitotic division maintains a population of spermatogonial stem cells in the male...
90.4K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
799
Infertility in Males01:23

Infertility in Males

Male infertility affects millions of couples worldwide, arising from various factors that impact different stages of the reproductive process. An endocrine imbalance resulting from conditions like hypogonadism, Klinefelter syndrome, or pituitary disorders can disrupt hormone levels and reduce sperm production. Testicular defects, such as tumors, cryptorchidism, atrophic testes, abnormal sperm morphology, and low sperm count or motility, may arise due to genetic factors, structural...
645
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
748
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
375